Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 11/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 3/20 | 0.33 |
| ▸ | JAK1 | P23458 | 3/20 | 0.33 |
| ▸ | JAK3 | P52333 | 3/20 | 0.33 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.33 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.33 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24370189 | 0.84 | SYK (0.36) | SYKMAPK1ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL22201891 | 0.82 | MAPK1 (0.35) | SYKMAPK1JAK2JAK1JAK3 | |
| SCHEMBL18352331 | 0.78 | JAK2 (0.34) | SYKMAPK1JAK2JAK1JAK3 | |
| SCHEMBL7950769 | 0.77 | MAPK1 (0.39) | SYKMAPK1ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL14616216 | 0.74 | MAPK1 (0.62) | SYKMAPK1ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL16946856 | 0.74 | MAPK1 (0.37) | SYKMAPK1ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL13199608 | 0.74 | JAK2 (0.40) | SYKMAPK1ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL25851514 | 0.74 | MAPK1 (0.37) | SYKMAPK1ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL12223458 | 0.73 | MAPK1 (0.50) | MAPK1JAK2IRAK4 | |
| SCHEMBL24126326 | 0.71 | IRAK4 (0.30) | IRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200216465-A1 | DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES | TURNING POINT THERAPEUTICS INC (US) | 2020-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200216465-A1 | DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES | MAP3K20, LCK, MAP3K1 | SYK 394/4885MAPK1 82/4885ALDH1A1 4630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.